Anika Therapeutics (ANIK) Free Cash Flow Growth (1y) (2011 - 2026)
Anika Therapeutics (ANIK) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.87 Bn | 42.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.59 Bn | 29.92 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.15 Bn | 19.49 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | -28.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -28.80% |
| Mar 31, 2026 | -112.49% |
| Dec 31, 2025 | 1,350.55% |
| Sep 30, 2025 | 31.13% |
| Jun 30, 2025 | 62.97% |
| Mar 31, 2025 | -52.74% |
| Dec 31, 2024 | -84.71% |
| Sep 30, 2024 | -33.84% |
| Jun 30, 2024 | 54.13% |
| Mar 31, 2024 | 61.37% |
| Dec 31, 2023 | 187.79% |
| Sep 30, 2023 | 464.24% |
| Jun 30, 2023 | -949.30% |
| Mar 31, 2023 | -56.71% |
| Dec 31, 2022 | -161.23% |
| Sep 30, 2022 | 30.85% |
| Jun 30, 2022 | -46.15% |
| Mar 31, 2022 | -6.46% |
| Dec 31, 2021 | 56.45% |
| Sep 30, 2021 | -86.09% |